All In Biotech

Drug Trial Radar · NCT04473417

Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects

An Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA-2811 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Mar 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Aug 4, 2020

Primary completion

Aug 26, 2020

Study completion Oct 12, 2020

Sponsor

Lead sponsor
Dong-A ST Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is the phase I study to evaluate the pharmacokinetics and safety of DA-2811 and Forxiga® after a single oral dose in healthy volunteers. The study will also compare the pharmacokinetics and safety profiles of DA-2811 under fasting and fed states in healthy subjects.

Conditions

  • Healthy

Interventions

  • ForxigaDrug

    single dose administration after 10hr fasting

  • DA-2811Drug

    single dose administration after 10hr fasting

  • DA-2811Drug

    single dose administration after 10hr fasting

  • DA-2811Drug

    single dose administration after high fat and calorie fed diet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUClastTime frame: pre-dose~48 hours post-dose
  2. CmaxTime frame: pre-dose~48 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bundangseoul national unversity hospital

    Sŏngnam, GyeonggiDo, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.